Test for sepsis therapy proves its worth:
This article was originally published in Clinica
A dry chemistry test developed by Cardiovascular Diagnostics has proved its viability in evaluating the effect of Eli Lilly's therapeutic anticoagulant on patients with sepsis. The next step will be to carry out further testing of patient samples in order to define the test parameters. As a result, Cardiovascular Diagnostics expects to alter the formulation of the test. Sepsis has a mortality rate of 30-50% and is caused by pathogens circulating in the blood which results in serious complications such as organ failure.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.